TSE:APS

Aptose Biosciences Competitors

C$6.61

+0.11 (+1.69 %)

(As of 04/9/2021 04:00 PM ET)

Add

Compare

Today's Range

C$6.40

Now: C$6.61▼

C$6.71

50-Day Range

C$4.45

MA: C$5.75▼

C$7.85

52-Week Range

C$4.32

Now: C$6.61▼

C$12.62

Volume24,779 shs

Average Volume64,934 shs

Market CapitalizationC$587.53 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Aptose Biosciences (TSE:APS) Vs. TRIL, CXR, BU, TH, BLU, and NRI

Should you be buying APS stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Aptose Biosciences, including Trillium Therapeutics (TRIL), Concordia International (CXR), Burcon NutraScience (BU), Theratechnologies (TH), BELLUS Health (BLU), and Nuvo Pharmaceuticals Inc. (NRI.TO) (NRI).

Aptose Biosciences vs. Trillium Therapeutics Stock

Trillium Therapeutics (TSE:TRIL) and Aptose Biosciences (TSE:APS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, profitability, valuation and risk.

Analyst Recommendations

This is a summary of current ratings and price targets for Trillium Therapeutics and Aptose Biosciences, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trillium Therapeutics	0	0	0	0	N/A
Aptose Biosciences	0	0	2	0	3.00

Trillium Therapeutics currently has a consensus price target of C$25.00, indicating a potential upside of 91.42%. Aptose Biosciences has a consensus price target of C$12.00, indicating a potential upside of 81.54%. Given Trillium Therapeutics' higher possible upside, analysts clearly believe Trillium Therapeutics is more favorable than Aptose Biosciences.

Earnings and Valuation

This table compares Trillium Therapeutics and Aptose Biosciences' revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trillium Therapeutics	C$148,000.00	9,091.97	C$-90,772,073.00	C($0.88)	-14.82
Aptose Biosciences	N/A	N/A	N/A	C($0.68)	-9.79

Aptose Biosciences has lower revenue, but higher earnings than Trillium Therapeutics. Trillium Therapeutics is trading at a lower price-to-earnings ratio than Aptose Biosciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Trillium Therapeutics and Aptose Biosciences' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Trillium Therapeutics	N/A	N/A	N/A
Aptose Biosciences	N/A	N/A	N/A

Summary

Aptose Biosciences beats Trillium Therapeutics on 3 of the 5 factors compared between the two stocks.

Aptose Biosciences vs. Concordia International Stock

Aptose Biosciences (TSE:APS) and Concordia International (TSE:CXR) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, risk, earnings and profitability.

Profitability

This table compares Aptose Biosciences and Concordia International's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aptose Biosciences	N/A	N/A	N/A
Concordia International	N/A	N/A	N/A

Valuation & Earnings

This table compares Aptose Biosciences and Concordia International's revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aptose Biosciences	N/A	N/A	N/A	C($0.68)	-9.79
Concordia International	C$569.62 million	2.15	C$17.20 billion	C$351.68	0.07

Concordia International has higher revenue and earnings than Aptose Biosciences. Aptose Biosciences is trading at a lower price-to-earnings ratio than Concordia International, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and recommmendations for Aptose Biosciences and Concordia International, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aptose Biosciences	0	0	2	0	3.00
Concordia International	0	0	0	0	N/A

Aptose Biosciences presently has a consensus target price of C$12.00, indicating a potential upside of 81.54%. Given Aptose Biosciences' higher possible upside, equities research analysts clearly believe Aptose Biosciences is more favorable than Concordia International.

Summary

Concordia International beats Aptose Biosciences on 3 of the 5 factors compared between the two stocks.

Aptose Biosciences vs. Burcon NutraScience Stock

Aptose Biosciences (TSE:APS) and Burcon NutraScience (TSE:BU) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, valuation, earnings, profitability and institutional ownership.

Profitability

This table compares Aptose Biosciences and Burcon NutraScience's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aptose Biosciences	N/A	N/A	N/A
Burcon NutraScience	N/A	N/A	N/A

Earnings and Valuation

This table compares Aptose Biosciences and Burcon NutraScience's top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aptose Biosciences	N/A	N/A	N/A	C($0.68)	-9.79
Burcon NutraScience	C$12,045.00	48,193.23	C$107,101.00	C$0.00	5,420.00

Burcon NutraScience has higher revenue and earnings than Aptose Biosciences. Aptose Biosciences is trading at a lower price-to-earnings ratio than Burcon NutraScience, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings for Aptose Biosciences and Burcon NutraScience, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aptose Biosciences	0	0	2	0	3.00
Burcon NutraScience	0	0	1	0	3.00

Aptose Biosciences presently has a consensus target price of C$12.00, indicating a potential upside of 81.54%. Burcon NutraScience has a consensus target price of C$5.00, indicating a potential downside of 7.75%. Given Aptose Biosciences' higher possible upside, analysts plainly believe Aptose Biosciences is more favorable than Burcon NutraScience.

Summary

Burcon NutraScience beats Aptose Biosciences on 3 of the 5 factors compared between the two stocks.

Aptose Biosciences vs. Theratechnologies Stock

Aptose Biosciences (TSE:APS) and Theratechnologies (TSE:TH) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, valuation, earnings, profitability and institutional ownership.

Profitability

This table compares Aptose Biosciences and Theratechnologies' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aptose Biosciences	N/A	N/A	N/A
Theratechnologies	N/A	N/A	N/A

Earnings and Valuation

This table compares Aptose Biosciences and Theratechnologies' top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aptose Biosciences	N/A	N/A	N/A	C($0.68)	-9.79
Theratechnologies	C$66.05 million	6.78	C$-27,589,254.00	C($0.29)	-16.22

Aptose Biosciences has higher earnings, but lower revenue than Theratechnologies. Theratechnologies is trading at a lower price-to-earnings ratio than Aptose Biosciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings for Aptose Biosciences and Theratechnologies, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aptose Biosciences	0	0	2	0	3.00
Theratechnologies	0	2	0	0	2.00

Aptose Biosciences presently has a consensus target price of C$12.00, indicating a potential upside of 81.54%. Theratechnologies has a consensus target price of C$3.75, indicating a potential downside of 21.38%. Given Aptose Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Aptose Biosciences is more favorable than Theratechnologies.

Summary

Aptose Biosciences beats Theratechnologies on 4 of the 6 factors compared between the two stocks.

Aptose Biosciences vs. BELLUS Health Stock

Aptose Biosciences (TSE:APS) and BELLUS Health (TSE:BLU) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, valuation, earnings, profitability and institutional ownership.

Profitability

This table compares Aptose Biosciences and BELLUS Health's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aptose Biosciences	N/A	N/A	N/A
BELLUS Health	N/A	N/A	N/A

Earnings and Valuation

This table compares Aptose Biosciences and BELLUS Health's top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aptose Biosciences	N/A	N/A	N/A	C($0.68)	-9.79
BELLUS Health	C$15,000.00	28,462.44	C$-42,145,306.00	C($0.54)	-10.13

Aptose Biosciences has higher earnings, but lower revenue than BELLUS Health. BELLUS Health is trading at a lower price-to-earnings ratio than Aptose Biosciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings for Aptose Biosciences and BELLUS Health, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aptose Biosciences	0	0	2	0	3.00
BELLUS Health	0	1	2	0	2.67

Aptose Biosciences presently has a consensus target price of C$12.00, indicating a potential upside of 81.54%. Given Aptose Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Aptose Biosciences is more favorable than BELLUS Health.

Summary

Aptose Biosciences beats BELLUS Health on 3 of the 5 factors compared between the two stocks.

Aptose Biosciences vs. Nuvo Pharmaceuticals Inc. (NRI.TO) Stock

Aptose Biosciences (TSE:APS) and Nuvo Pharmaceuticals Inc. (NRI.TO) (TSE:NRI) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, valuation, earnings, profitability and institutional ownership.

Profitability

This table compares Aptose Biosciences and Nuvo Pharmaceuticals Inc. (NRI.TO)'s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aptose Biosciences	N/A	N/A	N/A
Nuvo Pharmaceuticals Inc. (NRI.TO)	N/A	N/A	N/A

Earnings and Valuation

This table compares Aptose Biosciences and Nuvo Pharmaceuticals Inc. (NRI.TO)'s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aptose Biosciences	N/A	N/A	N/A	C($0.68)	-9.79
Nuvo Pharmaceuticals Inc. (NRI.TO)	C$76.09 million	0.14	C$-6,980,844.00	C($0.61)	-1.48

Aptose Biosciences has higher earnings, but lower revenue than Nuvo Pharmaceuticals Inc. (NRI.TO). Aptose Biosciences is trading at a lower price-to-earnings ratio than Nuvo Pharmaceuticals Inc. (NRI.TO), indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings for Aptose Biosciences and Nuvo Pharmaceuticals Inc. (NRI.TO), as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aptose Biosciences	0	0	2	0	3.00
Nuvo Pharmaceuticals Inc. (NRI.TO)	0	0	1	0	3.00

Aptose Biosciences presently has a consensus target price of C$12.00, indicating a potential upside of 81.54%. Given Aptose Biosciences' higher possible upside, analysts plainly believe Aptose Biosciences is more favorable than Nuvo Pharmaceuticals Inc. (NRI.TO).

Summary

Nuvo Pharmaceuticals Inc. (NRI.TO) beats Aptose Biosciences on 3 of the 5 factors compared between the two stocks.